GlassScriptPhysician profile
Charles Kim
NPI 1699208074
$2,280.17
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39.94 · 2022: $1,018 · 2023: $1,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,133 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,132.83 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $415.67 | 2022-2023 | Tukysa, Adcetris |
| Rigel Pharmaceuticals, INC. | $250.31 | 2022 | |
| Incyte Corporation | $238.73 | 2022-2023 | Jakafi |
| Eisai INC. | $193.28 | 2023 | |
| Genentech USA, INC. | $190.81 | 2022-2023 | Perjeta, Phesgo |
| Pfizer INC. | $186.21 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $145.60 | 2023 | Opdivo |
| Exelixis INC. | $84.99 | 2022 | |
| Kyowa Kirin, INC. | $75.50 | 2022-2023 | Poteligeo |
| Bayer Healthcare Pharmaceuticals INC. | $73.00 | 2023 | |
| Kite Pharma, INC. | $68.99 | 2022 | |
| Genzyme Corporation | $66.51 | 2022-2023 | |
| Array Biopharma INC | $53.74 | 2022-2023 | Braftovi, Mektovi, Xalkori |
| Celgene Corporation | $42.51 | 2023 | Pomalyst |
| Glaxosmithkline, LLC. | $40.05 | 2023 | Shingrix |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $38.73 | 2022 | |
| Daiichi Sankyo INC. | $20.57 | 2023 | Enhertu |
| Novartis Pharmaceuticals Corporation | $20.37 | 2023 | |
| Taiho Oncology, INC. | $20.09 | 2022 | |
| Alexion Pharmaceuticals, INC. | $20.07 | 2023 | Ultomiris |
| Janssen Biotech, INC. | $17.74 | 2023 | Imbruvica |
| Astellas Pharma US INC | $16.70 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.